Impact of HIV Drug Resistance Testing, and Subsequent Change to an Individualized Therapy in Tanzania

HIV Drug Resistance Clinical Trial

Official title:

Impact of HIV Drug Resistance Testing, and Subsequent Change to an Individualized Therapy Based on the Resistance Profile, in Children, Adolescents and Adults With Virological Failure of Their HIV Therapy, in Three HIV Clinics in Tanzania

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03557021
• Other study ID #: HIVDR2
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2017
• Est. completion date: September 30, 2020

Study information

• Verified date: June 2018
• Source: Medical Mission Institute, Germany
• Contact: Christa Kasang, PhD
• Phone: +4993180485
• Email: christa.kasang[@]medmissio.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current therapy regimens in Sub-Saharan countries, consisting of standardized first and second line drug combinations, yield a high rate of treatment failure, even within the first 12 months of therapy (23). These and other facts hint at the need for HIV resistance testing to improve treatment outcomes in resource-limited settings, but no prospective clinical data about this intervention exists. The proposed study aims to evaluate the impact of HIV drug resistance testing, and subsequent change to an individualized (second-line) therapy based on the resistance profile, in Tanzanian patients (children, adolescents and adults) with virological failure of their first-line and second-line therapy. Additionally, prevalence, patterns and clinical impact of HIVDR will be assessed, as well as the effect of enhanced adherence counselling.

The results of this study will help doctors to take evidence-based diagnostic and therapeutic decisions at an individual level, and will inform policy-makers in their decisions about future treatment and management concepts for HIV/AIDS.

Description:

HIV/AIDS is one of the main health challenges of our time, with a global burden of disease higher than any other infectious disease. The widespread use of antiretroviral drugs has changed its face from a fatal fate to a chronic disease. However, there are still many differences in the standard of care globally. Drug resistance testing is routinely performed in high income countries, but is often not available in resource limited settings. Instead, treatment consists of standardized therapy regimes, chosen from a limited amount of antiretroviral drugs. This may contribute to the high rates of virological failure seen in patients, and especially children and adolescents, on therapy. Virological failure persisting despite intensified enhanced adherence-counselling result in poor treatment success in HIV infected adults, children and adolescents on treatment and therefore early deaths. If therapy failure occurs, and HIV drug resistance is the likely reason, physician in Tanzania need to blindly choose a second-line therapy regimen, without knowledge of the exact resistance profile. However, multiple studies have discovered high rates of HIV drug resistance in patients with first line treatment failure, and even in therapy-naïve patients. To obtain information about presence of resistance mutations HIV genotypic resistance testing is required. This test is used to detect HIV genomic mutations that confer resistance to specific types of antiretroviral drugs as an aid in monitoring and treating HIV-infection. The test identifies mutation on the protease and reverse transcriptase gene, which are responsible for very crucial steps in the viral replication process. Results from this test can identify the medication for whom the virus is still susceptible and for whom it is already resistant. With this, it can be avoid switching to second-line regimen without the knowledge of the presence or absence of antiretroviral drug resistance. An individualized therapy can follow making sure that medication works best and the clinical outcome can increase.

While the positive impact of HIV resistance testing on treatment outcomes in high-income countries is well established, no prospective data has been published about the effect in resource-limited settings. This absence of data poses a hole in clinical knowledge, because the results from high-income countries are not readily transferable to low-income settings.

The proposed study aims to evaluate the impact of HIV drug resistance testing, and subsequent change to an individualized (second-line) therapy based on the resistance profile, compared to standardized second-line therapy. The study is designed as a randomised controlled trial. The study participants, Tanzanian patients (children, adolescents and adults) with virological failure of their first-line therapy, will be recruited at several study sites. All patients will first receive enhanced adherence counselling. The patients that still show virological failure three months after the counselling will be eligible for resistance testing. The regimen will be switched to individualized (second-line) ART or standardized second-line ART, and clinical, immunological and virological outcome parameters will be collected in a 6 month and 12 month follow up visit (Group I,II,III IV). In addition to the outcome of individualized therapy, the proposed study would yield insights about the prevalence and patterns of HIV drug resistance in patients with failure of their first-line therapy, and also about the effectiveness of enhanced adherence counselling.

For ethical reasons also 250 seconnd line treatment failure patients (Group V) with fast clinical progress will be included and transfered directly to the individualized therapy arm. With that we hope to bring them back to a working treatment.

The main diagnostic method of this study, HIV genomic sequencing, will be implemented and performed at the National Institute for Medical Research in Mwanza, Tanzania. This will contribute directly to the HIV-related diagnostic capacities of Tanzanian laboratories.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1250
• Est. completion date: September 30, 2020
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 99 Years

Eligibility

Inclusion Criteria:

1. Confirmed HIV positive patients on first-line ART

2. Virological treatment failure with > 1000 copies/ ml

Exclusion Criteria:

1. No consent given

2. HIV patients with psychiatric disorders

Related Conditions & MeSH terms

• HIV Drug Resistance

Intervention

Diagnostic Test:
• HIV Drug resistance testing
HIV Drug resistance testing by HIV pro DNA sanger sequencing

Locations

Country	Name	City	State
Tanzania	PASADA	Dar es Salaam
Tanzania	Baylor Hospital	Mwanza
Tanzania	Bugando Medical Center	Mwanza

Sponsors (2)

Lead Sponsor	Collaborator
Medical Mission Institute, Germany	National Institute for Medical Research, Tanzania

Country where clinical trial is conducted

Tanzania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viral Load	Viral load will be measured by plasma HIV viral load measurement (copies per ml) after switching first-line treatment failure patients to individualized therapy compared to standard second line therapy.	12 month
Secondary	Incidence of HIV related adverse events at 6 month	HIV related adverse events at 6 month will be determined according to CTC AE list version 4	6 month
Secondary	Incidence of HIV related adverse events at at 12 month	HIV related adverse events at 6 month will be determined according to CTC AE list version 4	12 month
Secondary	Prevalence of HIV Drug resistance mutations	The prevalence of HIV drug resistance mutations will be determined in patients with virological failure of first-line antiretroviral therapy	study start
Secondary	Pattern of HIV Drug resistance mutations	The patterns of HIV drug resistance mutations will be determined in patients with virological failure of first-line antiretroviral therapy	study start
Secondary	Viral load at 3th month	Viral load will be measured by plasma HIV viral load measurement (copies per ml) after enhanced conselling.	3 month